Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study to Determine Time to Steady-state

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male, age 18-75~* Morning serum testosterone (T) \<300 ng/dL on two occasions~* Naive to androgen-replacement therapy or willing to wash-out from current T therapy~Exclusion Criteria:~* Significant intercurrent disease~* Abnormal prostate digital rectal exam, elevated PSA, AUA symptom score \>15 or history of prostate cancer.~* Serum transaminases \>2 times upper limit of normal~* Serum bilirubin \>2.0 mg/dL~* Hematocrit \<35% or \>50%~* BMI \>36~* Untreated, obstructive sleep apnea.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Testosterone Undecanoate (Type: EXPERIMENTAL): Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).